Through the application of CRISPR-Cas9 technology, Shimokawa and team revealed that targeting LGR5+ CCSCs for elimination in CRC human organoids results in tumor shrinkage in xenograft models derived from these organoids. Here, LGR5 is linked to colorectal carcinoma.